drugset / Trial / NCT02041234

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

NCT02041234

Phase 4 Completed 40 enrolled Khoo Teck Puat Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with type 2 Diabetes (DM2). Investigators also hope to show that successful RYGB will reduce resource utilization in the near term with similar projected reduction over the medium to long term.

Timeline

Start
2014-02
Primary completion
2020-12
Completion
2022-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg
Comparator Empagliflozin Small molecule 25 mg
Comparator Linagliptin Small molecule 5 mg
Comparator Liraglutide Peptide 1.8 mg
Comparator Orlistat Small molecule 120 mg
Comparator Sitagliptin Small molecule 100 mg